Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Research & Development: 2021-2025

Historic Research & Development for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $24.2 million.

  • Kiniksa Pharmaceuticals International's Research & Development fell 7.26% to $24.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $97.5 million, marking a year-over-year increase of 1.04%. This contributed to the annual value of $111.6 million for FY2024, which is 46.69% up from last year.
  • According to the latest figures from Q3 2025, Kiniksa Pharmaceuticals International's Research & Development is $24.2 million, which was up 28.86% from $18.8 million recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Research & Development registered a high of $35.2 million during Q4 2024, and its lowest value of $13.8 million during Q2 2022.
  • In the last 3 years, Kiniksa Pharmaceuticals International's Research & Development had a median value of $23.8 million in 2023 and averaged $22.7 million.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Research & Development plummeted by 47.54% in 2022 and then spiked by 75.62% in 2024.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Research & Development (Quarterly) stood at $27.4 million in 2021, then plummeted by 47.54% to $14.4 million in 2022, then surged by 39.35% to $20.1 million in 2023, then surged by 75.62% to $35.2 million in 2024, then fell by 7.26% to $24.2 million in 2025.
  • Its Research & Development stands at $24.2 million for Q3 2025, versus $18.8 million for Q2 2025 and $19.3 million for Q1 2025.